MedTrace Logo

GLORIA-AF Registry Program - Second and Third Phases

NCT01468701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37235

Last updated 2021-03-29

Study results available
· View outcomes & findings →

Summary

In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-07
Primary Completion
2020-01-10
Completion
2020-01-10

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Ecuador
  • Hong Kong
  • Japan
  • Lebanon
  • Mexico
  • Peru
  • Russia
  • Saudi Arabia
  • Singapore
  • South Africa
  • South Korea
  • Taiwan
  • United Arab Emirates
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468701 on ClinicalTrials.gov